Loading…
Employees: 117
Size Aspen Neuroscience (ASPE) is a United States Health Care company (Biotechnology) with a market value of $349M, the 2957th largest of 3,085 United States companies the cockpit tracks. Shares closed at $12.01 on 18 Nov 2026.
Capital Return on invested capital runs 195.4 points below its cost of capital (8.9% WACC).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | $0 | $0 |
| Revenue growth | — | — | — |
| Gross profit | n/a | -$4.20M | -$3.70M |
| EBITDA | n/a | -$55.1M | -$49.8M |
| Net income | n/a | -$62.1M | -$48.6M |
| Free cash flow | n/a | -$62.5M | -$46.8M |
| Capital expenditure | n/a | $9.69M | $2.58M |
| Total debt | $349M | $350M | $237M |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ASPE | Peer median | Rank in peer set |
|---|---|---|---|
| ROIC minus cost of capital | -195.4 pp | -9.2 pp | lowest of 16 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $321M | -31% | n/a | n/a | n/a | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $319M | -79% | +395% | -173% | 9.5× | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| ProKidney PROK | United States | $314M | -38% | +4% | -24,830% | 1,625.4× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Nautilus Biotechnolgy NAUT | United States | $310M | +2% | n/a | -15,106% | 588.9× | n/a | n/a |